Connect your AI

Anika Therapeutics ANIK Increase Decrease In Accrued Income Taxes Payable

Increase Decrease In Accrued Income Taxes Payable at other companies

Globus MedicalGMED

——

Other financials

Income statement

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's increase decrease in accrued income taxes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Anika Therapeutics's increase decrease in accrued income taxes payable?: Anika Therapeutics (ANIK) reported increase decrease in accrued income taxes payable of -$65K in Q2 2026.
How has Anika Therapeutics's increase decrease in accrued income taxes payable changed year-over-year?: Anika Therapeutics's increase decrease in accrued income taxes payable increased by 85.1% year-over-year, from -$435K to -$65K.